Endoglin is a transforming growth factor b (TGF-b) coreceptor that serves as a prognostic, diagnostic and therapeutic vascular target in human cancer. A number of endoglin ectodomain-targeting antibodies (Abs) can effectively suppress both normal and tumor-associated angiogenesis, but their molecular actions remain poorly characterized. Here we define a key mechanism for TRACON105 (TRC105), a humanized monoclonal Ab in clinical trials for treatment of advanced or metastatic tumors. TRC105, along with several other endoglin Abs tested, enhance endoglin shedding through direct coupling of endoglin and the membrane-type 1 matrix metalloproteinase (MMP)-14 at the cell surface to release the antiangiogenic factor, soluble endoglin (sEng). In addition to this coupling process, endoglin shedding is further amplified by increased MMP-14 expression that requires TRC105 concentrationdependent c-Jun N-terminal kinase (JNK) activation. There were also notable counterbalancing effects on canonical Smad signaling in which TRC105 abrogated both the steady-state and TGF-b-induced Smad1/5/8 activation while augmenting Smad2/3 activation. Interestingly, TRC105-induced sEng and aberrant Smad signaling resulted in an excessive migratory response through enhanced stress fiber formation and disruption of endothelial cell-cell junctions. Collectively, our study defines endoglin shedding and deregulated TGF-b signaling during migration as major mechanisms by which TRC105 inhibits angiogenesis.
INTRODUCTION
Angiogenesis is a process in which new blood vessels are formed from pre-existing vasculature. As tumors require angiogenesis to grow and metastasize to distant organs, reducing tumor vascularization is a promising strategy in limiting cancer progression. 1 Endoglin is a transforming growth factor-b (TGF-b) coreceptor that is emerging as a unique vascular target in anticancer therapy. [2] [3] [4] [5] Numerous studies have shown that endoglin is required for both normal and tumor-induced angiogenesis, and is considered as the gold standard biomarker of tumor vasculatures for tumor progression, survival rate and metastases. 6 Despite a growing number of endoglin monoclonal antibodies (Abs) under evaluation for clinical applications, however, the underlying molecular mechanisms of antibody (Ab) action remain poorly defined.
As part of an integral TGF-b signaling complex in endothelial cells, the essential role of endoglin in angiogenesis during embryonic development and tumor growth is well established. 7 Endoglin knockout in mice is embryonic lethal due to defective angiogenesis, and multiple studies have shown that either depletion or targeted inhibition of endoglin expression impairs tumor vascularization. 5, 8, 9 These effects are mediated in large part by two canonical TGF-b signaling pathways.
In endothelial cells, TGF-b can either promote or inhibit angiogenesis depending on its association with two types of signaling receptors. The endothelial-specific receptor, ALK1, enhances a proangiogenic transcriptional response by phosphorylating and activating Smad1/5/8 transcriptional factors. 10 Alternatively, TGF-b can signal through ALK5, a ubiquitously expressed signaling receptor that suppresses angiogenesis by activating Smad2/3. 10 In addition, endoglin and ALK1 can each bind a structurally related TGF-b superfamily ligand, bone morphogenetic protein 9 (BMP-9), which signals through the ALK1/Smad1/5/8 pathway.
11 Although the precise mechanisms by which TGF-b and BMP-9 regulate angiogenesis is still an active area of investigation, endoglin is considered a critical component in modulating the balance between ALK1 and ALK5 signaling to exert either pro-or antiangiogenic signals.
The complex role of endoglin in angiogenesis is also evident at the level of extracellular domain shedding. 12 A recent study has demonstrated that endoglin is cleaved near the plasma membrane by membrane-anchored matrix metalloproteinase (MMP)-14 to release a soluble form of endoglin (sEng) into the circulation. 13 And although membrane-bound endoglin promotes angiogenesis, sEng antagonizes this process through multiple mechanisms including cell surface receptor downregulation and ligand sequestration. More recently, a surface plasmon resonance study demonstrated direct binding of sEng with BMP-9 but not TGF-b, suggesting that sEng inhibits angiogenesis in part by dampening the BMP-9/Smad1/5/8 signaling axis. 14 Overall, endoglin shedding has a critical role in regulating TGF-b signaling during angiogenesis.
Numerous preclinical studies have so far demonstrated the efficacy of endoglin-targeted therapies. Of particular interest is TRACON105 (TRC105), the first humanized monoclonal Ab currently in phase I/II clinical trials for treatment of advanced or metastatic solid tumors. 15 To date, it is unclear whether TRC105 and its variants inhibit angiogenesis by neutralizing endoglin signaling, by mediating Ab-dependent cell-mediated cytotoxicity or by inducing endothelial cell dysfunction through a combination of mechanisms. In the present study, we examined the mechanistic basis for how TRC105 and other endoglin-targeting Abs inhibit angiogenesis.
RESULTS
We chose to study the effects of TRC105 on two types of human endothelial cells, a human microvascular endothelial cell line (HMEC-1) and primary human umbilical vein endothelial cells (HUVEC), to define the mechanisms by which endoglin-targeting Abs inhibit angiogenesis. We first examined the effects of TRC105 on the steady-state TGF-b signaling to the canonical ALK1/Smad1/ 5/8 and ALK5/Smad2/3 pathways. A 24 h treatment with TRC105 in growth media caused a significant enhancement in Smad2/3 activation, whereas Smad1/5/8 activation was markedly reduced in a concentration-dependent manner (Figures 1a and b) . The Smads appeared as either single or doublet bands when immunoblotted with their respective phospho-specific and total Smad Abs, depending on the gel electrophoresis conditions as previously reported. 16, 17 We next tested for ligand responsiveness by subjecting the cells to serum deprivation, followed by a brief pretreatment with TRC105 (10 min) before either TGF-b or BMP-9 stimulation. Interestingly, TRC105 treatment abrogated TGF-binduced Smad1/5/8 activation, whereas its effect on Smad2/3 was enhanced ( Figure 1c ). Given that TGF-b-induced Smad1/5/8 activation first requires TGF-b binding to the endothelial-specific endoglin/ALK1 complex, these results suggest that TRC105 prevents the TGF-b/endoglin interaction, while presumably providing ALK5 a greater access to the ligand for Smad2/3 activation. In the case of BMP-9, there was a robust Smad1/5/8 activation irrespective of TRC105 treatment (Figure 1d ). Together, these results suggest that by targeting endoglin, TRC105 selectively inhibits the regulation of TGF-b but not BMP-9 signaling, and that overall, TRC105 attenuates the activation of Smad1/5/8 in favor of Smad2/3.
To determine the cellular effects of TRC105, we first tested its impact on endothelial cell growth using the MTT assay. We and others 18, 19 have previously reported that endoglin suppresses cell growth in part by downregulation of extracellular signal-regulated kinase (ERK) activation and c-Myc expression. Interestingly, endoglin targeting by TRC105 had minimal effect on cell growth relative to the control immunoglobulin G (IgG) over the course of 48 h treatment (Figure 2a, left graph) or by cell doubling time (data not shown), whereas endoglin depletion predictably yielded increased cell growth relative to the control (Figure 2a , right graph). We further compared the mitogenic response between endoglin targeting by TRC105 and endoglin depletion (Supplementary Figure 1A) . Here, endoglin depletion by short hairpin RNA (shRNA) stable knockdown caused a notable increase in ERK activation that activates c-Myc expression compared with the non-targeting control Ab, whereas endoglin targeting by TRC105 or control Ab had minimal effects (Supplementary Figure 1A) . In addition to proliferation, cells were assessed for TRC105 dose-dependent cytochrome c release as an indicator of mitochondrial dissolution and apoptosis. Consistent with the cell proliferation data, TRC105 did not induce a significant cytosolic cytochrome c release relative to untreated cells (B3-5%) (Figure 2b , graph). In comparison, TGF-b, as a known inducer of apoptosis, yielded 25-30% cytochrome c release (Figure 2b ; graph). Furthermore, there was no detectable difference in caspase cleavage relative to control IgG (Figure 2c ), indicating that TRC105 does not have a direct role in growth inhibition or apoptosis.
Although previous studies have established sEng as an antiangiogenic factor in vitro and in vivo, [20] [21] [22] [23] whether endoglin Abs regulate sEng production has not been examined. To test whether TRC105 has a functional role in regulating sEng production, we measured for endogenous sEng in the conditioned media of HUVECs and HMEC-1s upon TRC105 treatment for 24 h. Intriguingly, there was a distinct TRC105 concentration-dependent increase in sEng when released into the media from both cell types, whereas expression of total endogenous cellular endoglin remained constant (Figures 3a and b upper and middle panels). As TRC105 caused endoglin downregulation by promoting shedding rather than degradation, we explored the possibility that TRC105 regulates the MMP-14 activity. Notably, MMP-14 expression was moderately increased as a result of TRC105 treatment (Figures 3a and b third panels) . To test whether this was an epitope-related effect, three additional Abs targeting different epitopes were measured for their endoglin-shedding effects. Similar to TRC105, all three Abs tested significantly enhanced the level of sEng compared with no treatment (Figure 3c ), indicating a general role for endoglintargeting Abs in sEng production. Moreover, three of the four Abs tested, including TRC105, also promoted MMP-14 expression relative to the control (Figure 3c, third panel) .
To define the mechanism of Ab-induced endoglin shedding, we first examined their direct effects on MMP-14 proteolytic activity. We hypothesized that endoglin-targeting Abs promote the coupling of endoglin and MMP-14 into a complex at the cell surface. To test this, cells expressing myc-tagged endoglin and human influenza hemagglutinin (HA)-tagged MMP-14 were subjected to a brief pretreatment with TRC105 at 4 1C to allow TRC105 to react with membrane-localized endoglin while preventing their endocytosis. Although the immunoprecipitation with either anti-HA or MMP-14-specific Ab yielded a barely detectable transient interaction with full-length endoglin in the absence of pretreatment, TRC105 pretreatment dramatically enhanced their interaction, suggesting an Ab-induced coupling of endoglin/MMP-14 at the cell surface (Figures 4a and b) . To exclude the possibility of TRC105 non-specifically targeting MMP-14, a parallel experiment was performed in which cells expressing MMP-14 alone, or MMP-14 and endoglin, were treated with TRC105 and then immunoprecipitated with TRC105 (Supplementary Figure 1B) . As predicted, TRC105 failed to react with MMP-14 irrespective of pretreatment (lanes 1 and 2), and only coimmunoprecipitated MMP-14 when endoglin was co-expressed (lane 3, Supplementary Figure 1B) . To specifically examine whether the Ab-induced coupling of the endoglin/MMP-14 complex occurred at the cell surface, cells expressing MMP-14 and endoglin were pretreated with or without TRC105 at 4 1C before cell surface biotinylation, followed by immunoprecipitation of MMP-14. Consistent with the co-immunoprecipitation results, TRC105 pretreatment enabled the detection of biotinylated endoglin/MMP-14 complex, confirming TRC105 action at the cell surface (Figure 4c) . Finally, to demonstrate that endoglin shedding specifically requires MMP-14 proteolytic activity, we used an MMP-14 blocking Ab (a-MMP-14) that neutralizes its catalytic function. [24] [25] [26] Although TRC105 markedly enhanced endoglin shedding relative to the basal state, we repeatedly observed only slight increases in sEng upon MMP-14 inhibition (Figure 4d ), presumably through indirect proteolytic actions of other MMPs. However, the level of sEng upon co-treatment of TRC105 and a-MMP-14 was lower than TRC105 alone, indicating that the TRC105-induced shedding requires MMP-14 activity (Figure 4d ). Taken together, these biochemical studies indicate that TRC105 induces endoglin shedding by promoting its interaction with MMP-14 for proteolytic cleavage.
In addition to the biochemical approaches, we employed an immunofluorescence co-patching method to visualize TRC105-induced cell surface clustering of the endoglin/MMP-14 complex. Originally developed by Henis and co-workers [27] [28] [29] , this method provides a semi-quantitative analysis of two known interacting proteins to form heteromeric co-patched clusters at the cell surface. In control experiments, we measured the degree of random co-patching between MMP-14 with ALK3, another TGF-b superfamily membrane receptor. Upon expressing Myc-tagged ALK3 with HA-tagged MMP-14, each protein was allowed to aggregate into patched clusters by probing with its respective primary and then fluorophore-conjugated secondary Abs at 4 1C before fixation. This Ab-induced aggregation yielded mostly distinct green and red patches, indicating that TRC105 did not promote the dimerization of ALK3 and MMP-14 (Figures 5d and e ; random overlay image and graph). In contrast, endoglin and MMP-14 co-expression followed by immunoprobing with TRC105 and either anti-HA or MMP-14-specific Ab resulted in significant copatching and co-localization (Figures 5a-c , inset in image c and overlay in d). The level of TRC105-induced endoglin/MMP-14 copatching was significantly greater than the random control (60 versus 10%) regardless of whether HA or MMP-14-specific Ab was used (Figure 5e graph) . To further test whether this coupling is TRC105-specific or a general endoglin-Ab-directed effect, we used P3D1 Ab that also promoted sEng production (Figure 3c ). P3D1 and MMP-14-specific Abs yielded B40% co-patching (Figure 5e graph), strongly supporting a general role for endoglin-targeting Abs in endoglin/MMP-14 coupling at the cell surface. Taken together, these biochemical and immunofluorescence data demonstrate that endoglin-targeting Abs mediate endoglin/MMP-14 coupling at the cell surface to promote endoglin shedding. Given the observation that TRC105 also promotes MMP-14 expression (Figure 3 ) that likely further potentiates endoglin shedding, we measured the effect of TRC105 on gene expression and found that TRC105 typically amplified MMP-14 gene expression 1.5-2-fold relative to the control (Figure 6a ). As TGF-b has been shown to transcriptionally regulate several members of the MMP family in other cell types by Smad2/3 induction of Snail transcription factor, 30, 31 we tested this pathway as a possible mechanism for TRC105-induced MMP-14 gene expression. Contrary to expectations, blocking Smad2/3 activation with the ALK5 inhibitor (SB431542) markedly enhanced MMP-14 transcription relative to the control or TRC105 treatment (Figure 6b graph) . Co-treatment with the ALK5 inhibitor and TRC105 failed to suppress MMP-14 transcription, suggesting that the TRC105-induced MMP-14 expression is Smad2/3-independent. We next screened several small-molecule inhibitors to identify other potential signaling effectors mediating this process. Induction of MMP-14 mRNA by TRC105 was most sensitive to JNK inhibition (Figure 6c ). Consistent with this finding, there was a distinct concentration-dependent increase in JNK activation by TRC105 (Figure 6d ), supporting the novel role of TRC105 in JNKmediated MMP-14 transcriptional regulation.
Although sEng is a well-established antiangiogenic factor in vivo, the underlying molecular and cellular mechanisms have not been fully elucidated. Having ruled out growth inhibition and apoptosis as major cellular mechanisms, we tested whether TRC105 and sEng production disrupt cell motility. HUVEC and HMEC-1 were treated with either low or high concentrations of TRC105 and allowed to migrate in a transwell system. Interestingly, TRC105 increased the migratory response in both the HMEC-1 and HUVEC (Figures 7a and b) , a result consistent with the anti-migratory role for endoglin in previous studies using the endoglin knockout and knockdown systems. [32] [33] [34] Next, given that MMP-14 activity is required for efficient motility in many cell types, we examined whether the TRC105 enhances migration by upregulating MMP-14 activity. To do so, we co-treated cells with TRC105 in the presence or absence of the MMP-14 blocking Ab. Consistent with previous reports of MMP-14-neutralizing function, a-MMP-14 treatment alone effectively suppressed cell migration relative to the control (Figure 7c) . Furthermore, TRC105 treatment failed to override the inhibitory effects of a-MMP-14 in cells treated with both Abs (Figure 7c ), suggesting that MMP-14 activity mediates TRC105-induced migration. Finally, to specifically test the role of sEng in cell motility, we compared the migratory response of TRC105-treated cells with those expressing a secreted form of endoglin into the conditioned medium (Eng-E: extracellular domain). As predicted, the expression of Eng-ECD resulted in a significant enhancement of migration similar to that of TRC105 treatment, the effects of which were not significantly reduced even when incubated with a-MMP-14 Ab (Figure 7d) .
To determine the mechanisms by which increased endothelial migration might contribute to reduced angiogenesis, we examined several cellular properties including the actin cytoskeleton organization, and more the recently described phenomenon of endothelial-to-mesenchymal transition. 35, 36 Given that a-smooth muscle actin (a-SMA) is a marker of endothelial-to-mesenchymal transition, we tested for a-SMA expression in HUVEC and HMEC-1. Although a-SMA expression could not be detected by Role of endoglin antibodies in endoglin shedding S Kumar et al immunofluorescence staining or immunoblotting (data not shown), we observed a striking increase in actin stress fibers in HMEC-1 and HUVEC when treated with TRC105 ( Figure 8A ). Moreover, while the additional contractile forces generated by the stress fibers likely contribute to enhanced cell motility, we also measured how TRC105 influences endothelial cell-cell contacts during the maturation phase of angiogenesis. Near confluent monolayers of HUVEC were treated with or without TRC105 for 12-24 h, then stained with endothelial-specific adherens junctions markers ( Figure 8B ). Whereas untreated cells formed a complete monolayer accompanied by prominent vascular endothelial (VE)-cadherin and platelet endothelial cell adhesion (PECAM) staining along cell-cell junctions. TRC105 treatment prevented the formation of efficient cell-cell contacts as indicated by the reduced VE-cadherin and PECAM localization along cell membranes ( Figure 8B , I-III versus IV-VI). Taken together, our data here strongly support the role of TRC105 in perturbring normal endoglin regulation of endothelial migration and the formation of endothelial cell junctions.
DISCUSSION
Endoglin shedding is an important process in the regulation of angiogenesis and endothelial homeostasis. Not only does shedding reduce the overall cell surface level of endoglin, the resulting product acts as an antiangiogenic factor by sequestering circulating BMP-9. 14 The recent discovery of MMP-14 as the major protease responsible for endoglin shedding has raised an important question as to whether this proteolytic processing is actively regulated or whether it involves a general housekeeping mechanism. Our present study provides novel evidence that endoglin Abs have an important role in endoglin shedding-a key finding that is now supported by clinical evidence. Indeed, results from the first-in-human, phase I trial now reveal that, among the 37 plasma-based protein biomarkers tested, there is a dramatic dose-dependent increase in sEng levels in patients treated with TRC105 (personal communication with Drs Y Liu and A Nixon, Duke University, manuscript submitted).
Notably, our data indicate that TRC105 induces endoglin shedding through two overlapping mechanisms. First, we used multiple biochemical and immunofluorescence approaches to demonstrate that endoglin Abs enhance shedding by directly coupling endoglin and MMP-14 into complex at the cell surface (Figure 8 ). This process likely involves the stabilization of a preformed endoglin/MMP-14 complex, as our control experiments demonstrate that TRC105 specifically targets endoglin and does not directly react with MMP-14. Second, our small-molecule kinase inhibitor screening identified JNK signaling as the key mediator of TRC105-induced MMP-14 gene expression instead of Smad2/3, which has been previously shown to induce MMP-14 gene expression through Snail transcription factor. This finding was rather unexpected, as TRC105 promoted Smad2/3 activation at steady state and in rapid response to TGF-b (Figure 1) . Instead, the Smad2/3 upregulation may contribute toward pro-migratory phenotype through transcriptional regulation of known mediators of cell motility, including PAI-1 (schematic, Supplementary  Figure 2 ). Given that ALK5 is capable of eliciting mitogenic and pro-migratory signals through TGF-b-activated kinase (TAK1), our data is also consistent with the role of TRC105 in stimulating cell motility through ALK5/JNK-induced stress fiber formation. Our data here also reveal important clues as to how endoglin Abs may alter receptor oligomerization at the cell surface, not only with ALK1 and ALK5, but also another subset of TGF-b superfamily receptors such as ALK3 and ALK6, which are known to interact with endoglin in various contexts. 22, 23, 37, 38 How TRC105 and related Abs alter these heteromeric receptor complexes need to be studied to more fully understand the molecular basis for their antiangiogenic effects. Although it is clear that endoglin Abs cause endoglin shedding, the fate of the remaining membrane-anchored intracellular domain is unclear. Although this relatively short cytoplasmic domain lacks a catalytic function, it contains important structural (B) HUVEC were grown to near confluent monolayer (B80-90%) before either no treatment (I-III) or TRC105 treatment (IV-VI) (0.2 mg/ml) for 16-24 h. Cells were fixed, and then co-stained for VE-cadherin (green), PECAM (red) and DAPI (blue).
Role
To date, at least five binding partners have been identified: zyxin, zyxin-related protein 1, b-arrestin2, Tctex2b and GIPC. [32] [33] [34] 39, 40 Given that these proteins differentially regulate endoglin signaling, trafficking or exert distinct cellular effects during angiogenesis, it will be critical to define precisely how endoglin Abs affect these important interactions.
Apart from the mechanism of endoglin shedding, understanding the overall effects of TRC105 on endoglin signaling and biology appears to be much more complex than anticipated. For instance, endoglin depletion in HMEC-1 increased the mitogenic response (that is, ERK activation, c-Myc expression and cell proliferation), whereas TRC105 yielded no changes, suggesting that, overall, TRC105 alters rather than neutralizes endoglin function. This notion is consistent with our data showing that endoglin expression is not significantly altered by TRC105 even though a subpopulation of endoglin undergoes shedding. Another related but surprising finding in our studies was that TRC105 and its sEng byproduct minimally induced growth arrest or apoptosis, two widely recognized cellular outcomes of TGF-b signaling to the ALK5/Smad2/3 pathway (Figure 2 ). These results are in contrast with previous preclinical studies in which TRC105-induced apoptosis in HUVEC. 4 Although our results showed no such TRC105-related effects, a notable difference between the two studies is the markedly higher concentration of TRC105 used to induce apoptosis (50-100 mg/ml) compared with our experimental conditions (0.02-2 mg/ml). Preclinical pharmacokinetic studies suggest that TRC105 binds to human endoglin with a K d of 4.6 ng/ml (31 pM), and achieves saturation at 200 ng/ml in proliferating HUVEC. Although we also did observe growth inhibition and apoptosis at significantly higher doses (500-1000 mg/ml), these effects were relatively small (B10%) and statistically similar to that of IgG control (data not shown). Still, there are other discrepancies that cannot be accounted for, such as the recent study demonstrating that a relatively high dose of TRC105 (6 mg/ml or higher) effectively blocks BMP-9-induced Smad1/5/8 activation in HUVEC. 41 In direct contrast, our data indicate little or no effects on BMP-9/Smad1/5/8 activation either at low (0.2 mg/ml; Figure 1d ) or high concentrations (10 mg/ml; data not shown).
In our present work, a much more defined endothelial dysfunction was evidenced in uncontrolled migration of two different endothelial cell types. To date, the role of endoglin in endothelial migration remains controversial, with earlier studies demonstrating that endoglin and ALK1 together promote migration, whereas others 10, 23, 33, 42 have reported the opposite finding. Although certainly the varying experimental conditions may help explain these disparate findings, it is noteworthy that the role of sEng in these studies had not been examined as a critical variable. Our data suggest that the degree of sEng production may have a key role in fine-tuning cell motility, and is consistent with previous endoglin knockout and knockdown studies, demonstrating that endoglin inhibits migration and proliferation in certain contexts in order to facilitate neovessel maturation. 18, 19, 32, 33, 43 In summary, we have examined the multifunctional role of TRC105 to provide immediate and clinically relevant mechanistic insights for rapid improvement of existing antiangiogenic therapies. Importantly, our results demonstrate a previously unanticipated role of TRC105 in upregulating sEng production that contributes to deregulated endothelial migration and significantly alters TGF-b signaling to impair angiogenesis.
MATERIALS AND METHODS
Cell culture, transfection and Abs HUVEC were purchased from Lonza and maintained in endothelial growth medium (EGM)-2 growth medium (Lonza, Walkersville, MD, USA). HUVEC from passages 2 to 9 were used for experiments. HMEC-1 were maintained in MCDB-131 medium (Invitrogen, Grand Island, NY, USA), supplemented with 10% fetal bovine serum, 1 mg/ml hydrocortisone (Sigma), 10 ng/ml epidermal growth factor (Sigma, St Louis, MO, USA) and 2 mM L-glutamine. COS-7 cells were maintained in DMEM with 10% fetal bovine serum. Lipofectamine 2000 was used to transfect COS-7 cells as described according to manufacturer's protocol (Invitrogen). HMEC-1 were either transfected with Lipofectamine or Amaxa 4D nucleofection system according to manufacturer's protocol. Primary Abs used in this study were: TRC105 (TRACON Pharmaceuticals, San Diego, CA, USA), endoglin (H-300, Santa Cruz Biotechnology, Dallas 
Immunoprecipitation
Cells were washed with PBS, then lysed on ice with lysis buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 2 mM EDTA, 10 mM NaF, 10% (w/v) glycerol, 1% Nonidet NP-40) and supplemented with protease inhibitors (Sigma protease inhibitor cocktail) and phosphatase inhibitors (Sigma phosphatase inhibitor cocktail). The lysates were precleared by centrifugation and incubated with appropriate Abs and protein agarose G for 4-6 h at 4 1C. The immunoprecipitates were collected by centrifugation; pellets were washed with lysis buffer, and stored in 2 Â sample buffer before western blot analyses. For immunoprecipitation of sEng from the conditioned media, typically media from 10-cm plates of HUVEC and HMEC-1 were collected and concentrated by Amicon Ultra Centrifugal Filters (Millipore, Billerica, MA, USA) before immunoprecipitation with appropriate Abs.
Reverse transcriptase, real-time PCR and shRNAs Total RNA was extracted from the cells with Trizol reagent (Invitrogen), and 2 mg RNA was then converted to cDNA by using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Grand Island, NY, USA). Gene expression of MMP-14 was quantified by real-time reverse transcriptase PCR (Applied Biosystems, Step One) using the SYBR green assay reagent and gene-specific primer (Forward 5 0 -CCTGCCTGCGTCCAT CA-3 0 ; and Reverse 5 0 -TCCAGGGACGCCTCATCA-3 0 ). Relative amplification was quantified by normalizing the gene-specific amplification to that of 18s rRNA Forward (5 0 -GCTCTAGAATTACCACAGTTATC-3 0 ) and Reverse (5 0 -AAATCAGTTATGGTTCCTTTGGT-3 0 ) in each sample. The specific products were confirmed by SYBR green single-melting curve and a single correctsize product when running in 2% agarose gel. Changes in mRNA abundance were calculated using 2( À DDC T ) method. 44, 45 Quantitative PCR were run in triplicate. Statistical significance is presented as mean±s.d. The knockdown of human endoglin in HMEC-1 was achieved by transfecting cells with a shRNA vector purchased from Sigma (Mission shRNA) (5 0 -CCGGCCACTTCTACACAGTACCCATCTCGAGATGGGTACTGTGTAG AAGTGGTTTTTG-3 0 ) and stably selected using puromycin.
Immunofluorescence HMEC-1s and HUVECs grown on coverslips were serum starved for 3-4 h, washed with PBS and then fixed with 4% paraformaldehyde. Cells were permeabilized in 0.1% Triton X-100 in PBS for 4 min, then blocked with 5% bovine serum albumin in PBS containing 0.05% Triton X-100 for 20 min. All primary Abs were incubated at room temperature for 1 h unless noted otherwise. Cytochrome c was detected using cytochrome c Ab (Invitrogen). VE-cadherin (Cell Signaling) and PECAM Abs (University of Iowa Hybridoma) were used to detect endothelial cell-cell junctions. Actin was detected using Alexa Fluor-conjugated phalloidin for 30 min. Wherever appropriate, cells were co-stained with DAPI (Sigma) immediately before immunofluorescence microscopy analyses. 
Transwell migration assays
Cells were seeded in the upper chamber of a transwell filter in growth media, coated both at the top and bottom with gelatin to assess cell migration. Cells were allowed to migrate for 16 h at 3 1C through the gelatin-coated toward the lower chamber containing growth media with TRC105 (0.02-2 mg/ml). Migrated cells on the bottom surface of the filter were fixed, stained and then digitally imaged before counting.
Cell surface biotinylation assay Cells were washed briefly with cold PBS before biotinylation with membrane-impermeable biotinylation reagent (Sulfo-NHS-LC-Biotin, Thermo Scientific, Pierce, Rockford, IL, USA) according to manufacturer protocol. The biotinylation reaction was neutralized and cells were washed three times with cold PBS, then lysed and prepared for immunoprecipitation with MMP-14 (HA-Ab). The immunoprecipitated MMP-14 along with interacting proteins were resolved on SDS-PAGE and immunoblotted with streptavidin-horseradish peroxidase.
